Fennec Pharmaceuticals Inc.
FENC
Positions held
Your positionsFENC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $372.76M | Enterprise value | $331.51M | Trailing P/E | — | Forward P/E | 11.21 |
| PEG | 1.47 | Price / book | 8.78 | Beta | 1.23 | Dividend yield | 0.00% |
| Revenue growth | 85.2% | Earnings growth | — | Gross margin | 93.7% | Operating margin | 9.7% |
| Profit margin | -5.5% | ROE | -18.6% | ROA | -1.2% | Debt / equity | — |
| Current ratio | 5.85 | Free cash flow | $1.07M | Analyst recommendation | strong_buy | Mean target | $17.67 |
| 52w high | $13.25 | 52w low | $5.65 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $17.9M | $15.1M | $13.8M | $12.5M | $9.7M | — |
| Op margin | 9.7% | -0.8% | -18.7% | -1.6% | -28.3% | — |
| Net income | $2.0M | $0.2M | -$4.8M | -$0.6M | -$3.2M | — |
| Gross margin | 96.0% | 96.2% | 87.2% | 94.7% | 90.0% | — |
| Gross profit | $17.2M | $14.5M | $12.0M | $11.8M | $8.7M | — |
| Operating income | $1.7M | -$0.1M | -$2.6M | -$0.2M | -$2.7M | — |
- Revenue +18% vs prior quarter ($18M vs $15M).
- Gross margin 96% (was 96.2% prior quarter).
- Operating margin expanded to 9.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $44.6M | $47.5M | $21.3M | $1.5M | — |
| Op margin | -14.2% | 5.2% | -61.4% | -1481.3% | — |
| Net income | -$9.7M | -$0.4M | -$16.0M | -$23.7M | — |
| Gross margin | 91.6% | 93.3% | 94.1% | 94.4% | — |
| Gross profit | $40.9M | $44.4M | $20.0M | $1.4M | — |
| Operating income | -$6.3M | $2.5M | -$13.1M | -$22.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-14 · Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views
2026-08-11 · Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ...
2026-08-11 · Fennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings Beat
2026-08-11 · Adherex Technologies Q2 Earnings Call Highlights
2026-08-11 · Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates
2026-08-11 · Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-05 · Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Price (daily)
Full chart · RSI · MACD · patterns